NoticiasCon ayuda de IA

Novo Nordisk To Reveal The Huge Demand For Its Weight Loss Drugs

Novo Nordisk sees massive demand for weight-loss drugs Ozempic and Wegovy, boosting revenues sharply.

Por Mrudula Kulkarni

Editor Gerente - Pharma Now

23 sept 2024Updated Jun 26, 2025 · 2 min de lectura

Compartir Añadir como fuente preferida

Novo Nordisk To Reveal The Huge Demand For Its Weight Loss Drugs — https://www.leehealth.org/health-and-wellness/healthy-news-blog/exercise-and-nutrition/new-year-goals-will-weight-loss-drugs-work-for-you

Reportaje con ayuda de IA

Reviewed by Mrudula Kulkarni, Editor Gerente - Pharma Now

Pharma Giant Novo Nordisk will reveal the massive demand for weight loss drugs, such as Ozempic and Wegovy. The Danish company has experienced a significant boost in revenues, driven by the soaring demand for its diabetes and weight-loss medications, Ozempic and Wegovy. According to an analysis report, sales of £7.7billion are estimated between April and June. Last year it was about £3.9billion for the same quarter.

Wegovy, the drug used to treat obesity, is an injection that tricks the body into making it feel full. The medicine is available on the NHS and is prominently famous in the U.S. Celebrities like Rebel Wilson. Over the past year, a 64% rise has been noticed in shares. The current worth of Novo Nordisk is worth £210billion.

TemasNews

Written by

Mrudula Kulkarni

Editor Gerente - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.